Introduction
Emotional distress is common among cancer patients as a result of the diagnosis of a life-threatening disease, aggressive medical treatments, changes in lifestyle that occur, and the direct effects of the tumor [1] [2] [3] . Increasingly, attention is being paid to the psychological consequences of cancer, with recognition of not only psychiatric disorders such as major depressive disorder (MDD) or anxiety disorders, but also of subsyndromal symptoms of depression and anxiety. In addition, attention is being paid to the broader and more inclusive concept of emotional or psychological distress, as indicated by an elevated score on a one-item distress thermometer or another psychological symptom questionnaire. A number of major cancer organizations have recommended routine screening for distress, broadly defined, and several accrediting agencies mandate routine distress screening on the assumption that identification of distress will result in increased uptake of services and reductions in distress [4] [5] [6] .
Journal of Psychosomatic Research 75 (2013) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Well-accepted, standard definitions of medical screening define it as an intervention that involves the application of a screening tool to individuals who are not otherwise aware they are at risk, in order to detect a medical condition that can be alleviated through intervention [7, 8] . Screening for MDD, for instance, involves the use of depression symptom questionnaires or small sets of questions about depression to identify patients who may have depression, but who have not sought treatment and whose depression has not already been recognized by healthcare providers. Patients identified as possible cases based on a positive screen need to be further assessed to determine if they have depression and, if appropriate, offered treatment [9] .
Screening for "distress" is less well-defined since it does not seek to identify patients with a medical condition, and the meaning of a positive screen is less clear. If screening for "distress" is to be done, nonetheless, consistent with well-established definitions of screening [7, 8] , it would involve using scores above a pre-defined cutoff on a distress screening tool to identify patients to be offered an intervention to reduce psychological distress. Distress screening would be potentially useful if it could improve patient outcomes beyond existing standard care in which patients had access to the same services without being screened.
Three previous reviews [10] [11] [12] have sought to evaluate whether there is evidence that routine screening for psychological distress improves psychosocial outcomes among patients with cancer. The reviews have concluded that screening may improve communication between patients and health care providers and may stimulate discussions of psychosocial and mental health issues. The reviews agreed, however, that there is not conclusive evidence that screening for distress improves patient outcomes. One concern about these reviews is that they included studies that would not be considered "screening" based on any standard definition of screening. For example, some included studies used psychosocial questionnaires to inform psycho-oncology consultations that were provided to all patients. This is not screening, however, which, by definition, would involve using the questionnaires to actually determine which patients would receive the psychosocial consultations and potentially be offered psychosocial services [7] [8] [9] .
In a previous systematic review, we considered the evidence on screening for MDD in cancer patients [13] , but did not find evidence to support recommendations of systematic screening for depression. Compared to depression, the target of recommendations for screening for psychological distress is broader in scope, but less clearly defined in terms of targeting a specific medical condition. The objective of the present systematic review was to evaluate the evidence on screening for psychological distress in cancer. Review questions were developed based on the U.S. Preventive Services Task Force (USPSTF) [14, 15] analytic framework for evaluating screening programs. The USPSTF framework recognizes the need for RCTs to directly assess links between screening programs and patient outcomes. When direct evidence from screening RCTs is not available or is of low quality, the USPSTF framework assesses key links that are necessary for screening to benefit patients, such as the availability of effective treatments [14, 15] .
Screening for distress per se differs from other medical screening programs in that there is not a clear, defined medical condition, such as MDD, that screening tools seek to detect. Thus, although reviews of screening usually assess screening tool accuracy compared to a gold standard [14, 15] , we were not able to do this. Nonetheless, an important prerequisite if screening of psychological distress is to improve patient outcomes is that distress can be reduced through intervention for patients identified as distressed. Thus, consistent with USPSTF methods, Review Question #1 was, "What are the effects of interventions to reduce distress among cancer patients who have been selected for treatment based on a minimum threshold of psychological distress, as would be done in a screening program?" If screening is to be actually recommended as policy, there should be consistent evidence from wellconducted randomized controlled trials (RCTs) [16, 17] that screening benefits patients in excess of any possible harms. Thus, Review Question #2 was, "Is routine screening for psychological distress of cancer patients more effective than usual care in reducing symptoms of distress?"
Methods

Search strategy
The CINAHL, Cochrane, EMBASE, ISI, MEDLINE, PsycINFO, and SCOPUS databases were searched through April 6, 2011. A search was conducted for studies of interventions designed to reduce psychological distress among cancer patients identified as having distress (Review Question #1) and for studies that assessed outcomes of psychological distress screening interventions (Review Question #2). Search terms are reported in Appendix A. Manual searches were done on relevant systematic reviews (Appendix B), reference lists of included articles, and 45 selected journals (March 2011 to May 2012; Appendix C). We also tracked citations of included articles using Google Scholar [18] and searched the trial registries ClinicalTrials.gov [19] and the International Standard Randomized Controlled Trial Number Register [20] to attempt to identify unpublished treatment or screening RCTs.
Identification of eligible studies
Eligible articles included studies in any language on cancer patients with any type of malignancy at any disease stage that reported original data, excluding abstracts, case series, or case reports. Translators assisted reviewers to evaluate titles and abstracts and full-length articles for languages not covered by investigators, who were able to independently review material in English, Dutch, French, and Spanish. Multiple articles from the same cohort were treated as a single study. Studies with mixed populations were included only if cancer data were reported separately.
For Review Question #1, eligible articles were RCTs that compared interventions designed to reduce psychological distress to placebo, usual care, or attention controls in adult cancer patients with elevated distress. Only RCTs that limited inclusion to patients with high levels of distress, rather than all patients with cancer, were included because this is what would occur in a screening program. Indeed, patients with low levels of distress experience only negligible benefits from psychosocial interventions in cancer settings [21] . Small, underpowered studies are often of poor quality, and significant publication bias is a major problem among these studies [22] [23] [24] . A number of proposals have been made regarding setting thresholds for minimum number of patients for studies to be included in systematic reviews [23, 24] . In the present review, we included trials that randomized at least 25 patients to each group [25] . Head-to-head comparisons of different interventions without a comparison to usual care or placebo were not eligible. Detailed eligibility criteria that were used for determining study eligibility are shown in Appendix D.
Eligible articles for Review Question #2 were RCTs that compared outcomes between cancer patients who underwent screening for psychological distress and those who did not. Screening was defined according to the UK National Screening Committee's definition [7] . Thus, eligible screening trials had to include a strategy to identify patients with high levels of psychological distress based on an a prioridefined cutoff score on a measure of distress. Furthermore, in eligible studies, positive versus negative results of the screening test had to be used to make decisions about further assessment, referral, or treatment. Studies were excluded if questionnaires were used to inform and structure conversations that occurred as part of psychosocial consultations, but not to determine which patients receive services to address distress based on a score above a pre-defined cutoff. Finally, studies that involved administering multiple screening tools for multiple problems were not included, since patients in these studies could have been deemed in need of services due to reasons other than psychological distress (e.g., practical issues related to drug coverage by insurance, transportation and parking, or nutritional needs) [26] , and determining whether the psychological distress component of screening influenced distress outcomes would not be possible.
Two investigators independently reviewed articles for eligibility. If either deemed an article potentially eligible based on title and abstract review, then a full-text review was undertaken. Disagreements after full-text review were resolved by consensus.
Evaluation of eligible studies
Two investigators independently extracted and entered data into a standardized spreadsheet (see Appendix E). Discrepancies were resolved by consensus. Risk of bias in studies included for both review questions was assessed with the Cochrane Risk of Bias tool [27] (see Appendix F), including assessment of financial conflicts of interest as has been recommended [28, 29] . Risk of bias was assessed by two investigators, with discrepancies resolved by consensus.
Data presentation and synthesis
Psychological distress outcomes reported in each eligible study were classified as primary or secondary for the purposes of the review. For both review questions, when multiple measures of psychological distress were assessed as outcomes, designated primary outcomes for each study were prioritized. If there were no designated primary outcomes, the distress measure that was used to determine eligibility for the trial (Review Question #1) or as the screening tool for psychological distress (Review Question #2) was selected. If multiple instruments were used for distress selection, continuous scores on interview-based observer-rated instruments were prioritized over self-rating instruments. This is because observer-rated instruments, particularly the Hamilton Depression Rating Scale, are used most often as outcome measures in depression trials and considered the gold standard [30] . If there were no observer-rated instruments, and there was more than 1 self-rating instrument, all were reported as secondary outcomes. When outcomes were assessed at multiple time points, the assessment point that followed the end of treatment most closely was reported. Post-intervention effect sizes were reported using the Hedges's g statistic [31] , which represents a standardized difference between 2 means, as well as r 2 , which is statistically equivalent [32, 33] , but presents results in terms of percent of variance in distress outcomes due to treatment. Dichotomous outcomes were not extracted since there is no agreed upon gold standard or definition for psychological distress "caseness."
Eligible studies for each review question were evaluated to determine whether there was sufficient clinical and methodological similarity to support pooling of results. Results from trials with a high degree of clinically heterogeneity in terms of patients, interventions, or study procedures should not be synthesized meta-analytically because the effect estimate that is generated would not be expected to generalize to any given intervention [24] . For Review Question #1 (treatment), studies were heterogeneous in terms of patient samples, therapeutic interventions, outcome measures, and treatment duration. Only • Incomplete outcome data (1) Fig. 1 . PRISMA flow diagram of study selection process for review question #1. Assessed using PHQ-9 and 3 additional questions from PRIME-MD. c Treatment components received varied between study participants. Effects of collaborative intervention were assessed after 8 months. d The PHQ-9 was used to determine eligibility for the trial and was thus classified as the primary outcome, but continuous outcome data were not reported for the PHQ-9. e Enhanced usual care consisted of standard oncology care, educational pamphlets, and a listing of center and community resources. f Results adjusted for sex, race, years in the US, dysthymia, baseline depression severity, baseline anxiety, cancer stage, cancer type, and treatment status. g Results from social support group were not included in this review, as fewer than 25 patients were randomized to this group. h The fourth assessment visit (mean 12.3 weeks post-randomization) was closest to the end of the treatment period. However, only 33/163 patients completed the fourth visit. Outcome data presented here were assessed at the fifth visit (mean 14.9 weeks post-randomization). i Planned treatment duration was 8 weeks, but 28 patients (39%) received additional therapy sessions between 8 weeks and 4 months. j No primary outcome could be identified. k Eligible participants met study criteria for depression, cancer-related pain, or both. Results are reported only for the 309 participants meeting eligibility criteria for depression. l Age and sex were reported for the whole sample (N = 405), and not only the 309 participants enrolled for depression. m Treatment duration was not explicitly stated in the article, but 16 weeks was the last assessment timepoint. n HADS-A and HADS-D were identified in the article as primary outcomes, but insufficient information was provided to extract continuous outcome data. The authors reported that anxiety was significantly reduced in the treatment group at 16 weeks, but not depressive symptoms. o Anxiety and depression outcomes were assessed at 6 weeks. 5 study was identified for Review Question #2 (screening). Therefore, results were not pooled quantitatively in a meta-analysis, but were summarized in a systematic review. A review protocol was not published or registered for this systematic review. However, a written protocol was developed and followed for searching, data extraction, and data synthesis with all methods determined a priori.
Results
Review question #1: effect of treatment of psychological distress
The combined database search for Review Questions #1 (treatment) and #2 (screening) generated 4167 unique citations. As shown in Fig. 1 , for Review Question #1 (treatment), 3754 were excluded after title/abstract review and 399 after full-text review, leaving 14 eligible studies for review. No additional studies were identified through alternative sources, such as hand searching of journals, forward citation of included articles, and review of trial registries.
As shown in Table 1 , the 14 studies of interventions to reduce psychological distress we reviewed included 12 studies of patients with mixed cancer sites [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , 1 study with patients with breast or cervical cancer [46] , and 1 study with patients with breast cancer only [47] . Total sample size per study ranged from 55 to 472. Of the 14 studies, 7 randomized at least 64 patients per group [35, [37] [38] [39] [40] 44, 45] , which would provide adequate (80%) power to detect a medium effect size (standardized mean difference = 0.50) [48] .
Four studies were pharmacological interventions designed to treat depression, 2 with mianserin [34, 47] and 2 with fluoxetine [38, 43] . The other 10 studies included collaborative care interventions [35, 37, 40, 44, 46] , cognitive behavior therapy [36, 39, 41] , problem solving therapy [42] , and aromatherapy massage [45] . Among the drug trials, there was 1 study [38] with at least 64 patients per group, and that study found a small effect size reduction on self-reported depressive symptoms with fluoxetine (Hedges's g = 0.23). Three other smaller trials [34, 43, 47] reported somewhat larger effects for fluoxetine (Hedges's g = 0.36) [43] and mianserin (Hedges's g = 0.60 to 0.77) [34, 47] . Among collaborative care trials, effect sizes were small to moderate for adequately powered trials (Hedges's g = 0.17 to 0.47) [35, 37, 40, 44] and moderate to large for a smaller study (Hedges's g = 0.60) [46] . The effect sizes for outcomes reported in a trial of problem-solving therapy trial [42] , comparing problem-solving therapy to a wait-list control (Hedges's g = 3.76) or problem-solving therapy with a significant other to the wait-list control (Hedges's g = 4.30) were exceedingly large. The effect sizes on 2 outcome measures from aromatherapy with massage [45] were small (Hedges's g = 0.17 to 0.22) and not statistically significant. Effect sizes for each individual study are shown in Table 1 .
Risk of bias ratings are shown in Table 2 , and specific explanations for all ratings are available from the authors. Among the 4 trials of antidepressants, all had unclear or high risk of bias for the majority of rating categories [34, 38, 43, 47] . Specifically, all had unclear or high risk related to industry funding and author-industry financial ties, and all were conducted prior to the availability of clinical trial registries. Thus, selective outcome reporting was rated as unclear for all of these trials. Among non-pharmacological treatments, all were rated as high risk for blinding of patients and personnel and for blinding of outcome assessment due to the nature of the interventions and outcome assessments. Generally, quality was mixed in these studies. Not including blinding, only 1 non-pharmacological intervention trial [44] was rated as low risk of bias across all categories, including being registered with sufficiently precise outcome registration to compare to those described in the published trial report. One trial of problem-solving therapy [42] was rated as high risk of bias for Other Sources of Bias. This was due to the unrealistically high effect sizes, approximately 10 times those of other non-pharmacological studies, which were reported for the primary outcome variable. Other meta-analyses have excluded this study as an extreme outlier [49] [50] [51] .
Review question #2: effect of screening for psychological distress
For Review Question #2, 4142 of the original 4167 citations were excluded after title and abstract review and 24 after full text review, leaving 1 RCT [52] of screening for psychological distress among newly diagnosed breast cancer patients (Fig. 2 ). In this study, the usual care group (N = 127) received a brief psychosocial intervention in the first 2 weeks post-randomization as part of standard care (mean 2.2 social work contacts). The intervention group (N = 123) received the same brief intervention (mean 2.4 social work visits) plus telephone screening with the General Health Questionnaire, beginning 21 days post-randomization and continuing monthly for 12 months. Once screening was initiated, 80% of screened patients had at least 1 positive screen, which triggered a social work telephone contact beyond referrals that occurred as part of usual care (mean = 6.1 social work contacts versus 2.4 for usual care). As shown in Table 3 , at 12 months post-randomization, Psychiatric Symptom Index scores for the intervention and usual care groups were equivalent. In addition, women in the intervention group were somewhat more likely to have a diagnosis of MDD at 12 months post-randomization (n = 22, 18%) compared to women in the control group (n = 15, 12%), although this was not statistically significant. Risk of bias in this screening RCT was generally low ( Table 2) .
A number of other studies (see Table 4 ) described by their authors or in other reviews [10] [11] [12] as related to screening were excluded from the present systematic review. Several studies were excluded because decisions about whether patients should receive further assessment, referral, or treatment were not based on a pre-specified cutoff score on a measure of distress. In those studies, a range of screening tools was often made available for clinical consultations, but a positive screen on a distress screening tool was not used to determine referral for psychosocial evaluation or treatment. Studies were also excluded because they (1) were not RCTs; (2) included multiple screening tools for many practical or logistical issues, not allowing the effect of screening for psychological distress to be evaluated separately; or (3) did not report distress symptom or diagnosis outcomes.
Discussion
Several clinical recommendations [4] [5] [6] have been made for screening for psychological distress to be part of standard cancer care. Guidelines and recommendations, however, vary in the degree to which they are evidence-based [53] and none of these recommendation statements have been based on a systematic review that found benefits from screening, defined according to standard definitions.
There are well-established procedures for evaluating screening programs [8, 16, 17] . The principal criterion is whether there is evidence from well-conducted RCTs that benefits from screening outweigh possible harms (e.g., economic costs, drug side effects). The main findings of this systematic review are that (1) treatment of distress with pharmacological or behavioral interventions can improve psychological distress in adult cancer patients with psychological distress; and that (2) only 1 RCT of distress screening, with screening defined based on standard definitions of medical screening has been conducted with adult cancer patients. In that study [52] of telephone screening for psychological distress among newly diagnosed breast cancer patients, monthly telephone screening did not improve psychological distress. The authors of that study concluded that a brief psychosocial intervention, which was provided as part of standard care, may have reduced distress and reduced the potential impact of screening. Additionally, the fact that 80% of patients in that study had at least 1 positive screen in a 12-month period suggests that screening may not have effectively identified patients with substantially elevated distress.
Several reviews on screening for distress in cancer patients have been published previously [10] [11] [12] and they each concluded that there was no evidence that distress screening improved distress outcomes among cancer patients. Two of these reviews included 7 studies [10, 12] , and one included 14 studies [11] . The authors of those studies were consistent in arguing that evidence for benefits of screening for distress on patient outcomes in cancer patients is inconclusive and scarce and in calling for high-quality trials to determine if distress screening would improve patient outcomes.
Two of the reviews [10, 11] concluded that there is evidence that the use of distress questionnaires may improve communication about psychosocial issues between patients and oncology staff. It is important to keep in mind, however, that using questionnaires to facilitate conversations with patients, while potentially helpful, is not screening and does not inform the question of whether screening with these tools to determine who receives subsequent assessment will benefit patients. Consistent with this, a major shortcoming of previous reviews on distress screening [10] [11] [12] is that they all included studies that would not be considered trials of screening interventions in the context of any standard definition of medical screening. Indeed, with the exception of 1 study [52] , all of the studies included in these reviews were excluded from the current review for a number of reasons (see Table 4 for excluded distress screening studies). Five studies [26, [54] [55] [56] [57] screened for multiple problems at the same time (i.e., fatigue, pain, perceived support, and psychological distress), which made it impossible to assess the specific effects of screening for psychological distress. One of those studies [26] screened simultaneously for multiple problems with substantially different possible care responses (e.g., psychological distress, pain, fatigue, weight change, transportation, parking, drug coverage, finances). It was not possible, however, to determine in this study how many patients screened positive for psychological distress versus other practical or logistical issues, such as difficulties with transportation, parking, drug coverage, or finances, none of which would be best managed through psychological intervention. Six studies [55] [56] [57] [58] [59] [60] did not use a defined cutoff score to indicate a positive screen for heightened distress or to determine which patients would receive further assessment or treatment. In addition, 6 of the studies [58, [60] [61] [62] [63] [64] were not RCTs, but were, for example, sequential cohort designs. Finally, 3 of the studies [62-64] did not assess distress as an outcome, but investigated other outcomes, such as referral rates.
Distress screening can benefit patients only to the extent that it identifies patients with significant psychological distress who are not already recognized as distressed or receiving supportive services, successfully engages those patients in treatment, and achieves positive treatment results. In many cancer care settings, however, high numbers of patients are already treated with antidepressants as an attempt to address distress, even though many of these patients do not have depression or a history of depression [65] . Furthermore, as illustrated by one study from Austria [66] , the desire for psychosocial support to cope with cancer may not be correlated with distress levels, and nearly as many patients with low levels of distress may desire supportive care as patients above the cutoff criterion on a screening tool. Thus, better patient psychosocial care may be best achieved by providing more information and coordinating care pathways, rather than seeking to automate triage processes through mechanized screening and numerical algorithms.
Beyond screening for distress in cancer care settings, a number of other systematic reviews have concluded that there are no RCTs that have shown that depression screening improves depressive symptoms in cancer [13] , cardiovascular disease [67] , or perinatal care [68] . A 2008 meta-analysis of depression screening in primary care [69] reviewed 11 trials and found several trials where screening increased identification or treatment of depression, but none where screening improved depression outcomes. The U.S. Preventive Services Task Force has recommended depression screening in primary care [70] , but specifies that screening should only occur when integrated depression care systems for evaluation and case management are available. No trials, however, have shown that patients screened and referred for such collaborative care would have better outcomes than patients who are not screened, but who could potentially access collaborative care via other pathways [9] . This was an important reason why the UK National Institute of Clinical Excellence [71] did not recommend routine depression screening in primary care.
Given the current lack of evidence for benefits of distress screening, potential costs from implementing such a program must be carefully considered. An important concern is that routine screening would either take time or consume resources that could be devoted to other patient needs. Some might assume that screening questionnaires are easily and inexpensively implemented. However, this confuses the cost of administering a questionnaire and the cost of screening. The cost of screening includes assessments, consultations, a Authors of study did not provide data on number of patients who were approached or eligible for the trial, but they did not that the patients enrolled represented a small fraction of eligible patients. b Effect sizes reported are much higher than seen in any other psychotherapy trials of this size and larger than normally considered plausible. This trial has been excluded as an extreme outlier in other reviews [47] [48] [49] .
treatment and follow-up services, which is much larger than the cost of administering a questionnaire [7, 8] .
Another concern is that attention and potentially limited mental health resources could be devoted only to those who screen positive for distress even though many other patients might like to discuss their psychosocial needs or might have self-referred or been referred by their clinicians. It is important that the psychological needs of cancer patients are recognized and addressed, and there are many alternatives to screening to meet this need. As long as there is no evidence that screening leads to improvements in distress, focusing on the availability and implementation of psychosocial support might better benefit cancer patients.
Without high-quality evidence from well-designed RCTs that demonstrate sufficient benefit to justify costs and potential harms from screening, recommendations for implementation of screening programs are premature. Research is needed that compares the benefits and harms of screening for psychological distress in trials in which patients in the screening group may access psychosocial resources via screening or other referral processes and patients in the non-screened group can access the same services via self-or other referral processes. Trials should clearly differentiate psychosocial needs that are best managed in the context of mental health services versus practical or logistical issues that are best addressed via other mechanisms (e.g., parking, insurance). They should also differentiate problems, such as fatigue and pain, which may or may not be related to psychological issues and for which first-line interventions are usually not psychological, from psychological distress. Reported distress outcome was assessed at the end of the intervention period. A continuous outcome that favored the treatment group is reported in this table as a positive number. b 11 patients were eliminated post-randomization, including 1 who was found to have metastatic breast cancer, 1 who did not have breast cancer following re-examination, and 9 with incomplete or unavailable outcome data. Only number of PHQ-9 symptoms and EORTC QLQ-C30 emotional function symptoms discussed with clinician, but not distress outcomes were assessed.
Funding/support
A positive distress screen based on a defined cutoff score was not used to determine who received further assessment or treatment. Distress symptoms were not an outcome, only the discussion of symptoms.
Boyes, 2006, Australia [54] Mixed 80 Intervention: Results from a computer survey completed prior to each visit were provided to the patient's oncologist.
The survey included and assessment of 12 physical symptoms associated with chemotherapy, symptoms of anxiety and depression (HADS), and perceived supportive care needs (31 items), along with computer-generated suggested strategies to manage each identified issue. Control: Results from computer survey not made available to oncologist.
No significant difference after 4 visits between groups for change in HADS-D scores and proportion of patients with HADS-D ≥ 11.
Screening of multiple problems and perceived care needs did not allow assessment of the effect of distress screening. In addition, a positive distress screen based on a defined cutoff score was not used to determine who received further assessment or treatment.
Bramsen, 2008, The Netherlands [73] Mixed 129 Intervention: Patients were offered the possibility of psychosocial support by head nurse and information leaflet. Those who accepted were screened using a semi-structured interview with a checklist. Results were discussed in an interview, and patients were asked if they wanted a follow-up contact. Control: Usual care with no screening.
No significant difference between groups on EORTC QLQ-C30 emotional functioning subscale, IES total score or GHQ-12 total score. Not a randomized controlled trial (sequential cohort design). A positive distress screen based on a defined cutoff score was not used to determine who received further assessment or treatment, which was based on whether patients requested it following an interview.
Carlson, 2010, Canada [26] Lung and breast 1134 Full screening intervention: Results from DT, problem checklist, fatigue and pain thermometers, and PSSCAN, depression and anxiety sections, along with personalized feedback report placed on patient's electronic medical record at initial visit. Triage intervention: Full screening, as described above, along with an offer to speak to a member of the study psychosocial team about any of the assessed issues. Control: DT completed, but results were not disclosed to patient or placed on electronic medical record.
No difference between full screening intervention, triage intervention, or usual care groups on PSSCAN depression scores 3 months post-randomization.
Screening of multiple problems did not allow assessment of the effect of distress screening. A positive distress screen based on a defined cutoff score was not used to determine who received further assessment or treatment.
Grassi, 2011, Italy [61] Mixed 3375 c Intervention: Following a staff educational intervention, the DT was introduced into clinical practice, with referral to psycho-oncology services for assessment and intervention following positive screens (DT >4). Control: Physicians and nurses were able to refer patients to psycho-oncology services based on clinical judgment.
Only proportion of patients referred to psycho-oncology services and characteristics of referred patients were reported, but not distress outcomes.
Not a randomized controlled trial. In addition, distress was not an outcome. Only proportion of patients referred to psycho-oncology services was reported. A positive distress screen based on a defined cutoff score was not used to determine who received further assessment or treatment.
Shimizu, 2010, Japan [63] Mixed e 1065 Intervention: Patients completed 11-point DIT (score range 0-10), and those with a distress score ≥ 4 and an impact score ≥ 3 were referred by their oncologist for a psycho-oncology service consultation.
Control: Usual care with referral to psycho-oncology services by physician of patients considered moderately or severely distressed.
Only number of positive screens and number diagnosed and treated, but not depression outcomes, were assessed.
Not a randomized controlled trial (sequential cohort design). In addition, outcomes included number of positive screens and number treated, but no distress outcomes were assessed.
Taenzer, 2000, Canada [60] Lung 57
Intervention: At a single clinic visit, patients completed the EORTC QLQ-C30, which was provided to clinic staff prior to clinic appointment with no specific instructions for use.
Control: Patients completed the EORTC QLQ-C30
Only number of quality of life issues addressed in appointment and patients satisfaction, but no depression outcomes, were assessed.
Not a randomized controlled trial (sequential cohort design). In addition, a positive distress screen based on a defined cutoff score was not used to determine who received further assessment or treatment and no distress outcomes were assessed.
(continued on next page) 11 Scores on FACT-Emotional Subscale were better in the intervention group than the usual care group, but not different from the attention control group.
A positive distress screen based on a defined cutoff score was not used to determine who received further assessment or treatment. In addition, screening of multiple problems did not allow assessment of the effect of distress screening. 
Abbreviations
. #1 AND #2 AND #3 AND #4
Scopus TITLE-ABS-KEY ("major depressive disorder" OR depress* OR distress OR anxiety OR "quality of life") AND TITLE-ABS-KEY (screen* OR assess* OR treatment OR "drug therapy" OR intervention OR antidepress* OR psychotherapy OR treatment OR psychologic*)AND TITLE-ABS-KEY (neoplasm* OR cancer OR malignan* OR tumor OR tumour OR oncol*) AND (TITLE-ABS-KEY (randomized OR controlled OR trial)) Appendix B. Relevant systematic reviews Note: If a study claims that its primary objective/outcome is to improve survival via reducing psychological distress, then count this as an intervention designed to reduce psychological distress.
(2) There are multiple outcomes declared without identification of a primary outcome, some of which are psychological and some of which are not primarily psychological (e.g., physical health or quality of life, fatigue, pain). However, the mechanism of the intervention is known to primarily target cognitions and behaviours related to mood/psychological distress or to target physiological indices of stress that are known to be related to mood/psychological distress. Examples of interventions whose mechanism is known to primarily target cognitions and behaviours related to mood/psychological distress include psychological therapies (e.g., CBT, psychodynamic therapy, behavioural therapy, expressive writing) that can be delivered via a variety of mechanisms (psychotherapy, bibliotherapy, online resources, group delivery Minimum level of distress: In addition, the study must include patients with a minimum level of general, psychological or emotional distress and must exclude patients scoring below that level, or studies must perform separate analyses on patients with distress scores above a cutoff level. Inclusion standards may include a self-report questionnaire or a clinical interview (structured or unstructured) for depression or anxiety disorders. Studies that do not provide separate analyses for patients above a distress cutoff, but, instead, analyze the association between distress and treatment outcome continuously are excluded. Authors will not be contacted for original data if the sample was not dichotomized in the study.
Sample size: There must be at least 25 subjects randomized to each group (distressed vs. non-distressed).
Complete distress outcome data: Outcomes have to be continuous, or a dichotomous response or remission outcome based on defined criteria must be reported.
Review Question #2: Distress screening
Original data: The article must be an original report of a study, and not, for example, a letter, editorial, systematic review or meta-analysis, or a case series or case report study.
(Adult) cancer: The study sample must consist of cancer patients or survivors of cancer and not, for example, concern partners of cancer patients. When the sample includes cancer patients as well as other patients, data for cancer patients must be separately reported. Only studies on adult patients (≥ 18 years) will be included.
RCT of screening for distress: The study needs to be a randomized controlled trial in which the intervention group patients are screened for distress with any measure or screening method and the control group is not screened. A cutoff on a distress screening tool that would be used to identify possible cases and make decisions regarding further assessment or treatment needs to be defined a priori. Studies in which questionnaire results were provided to clinicians without guidance on cutoff scores to determine positive screening status are also excluded.
Studies in which both intervention and control groups received the same psychosocial services, but service providers in the intervention group had access to results from psychosocial questionnaires that may have informed their interactions, but did not necessarily determine service allocation decisions, are excluded. Studies that administered multiple screening tools for multiple problems may be included if all of the measures have defined cutoffs for positive screens and all are screens for psychological or general distress. General or psychological distress must be an outcome of the study. Distress outcome measures can be any measure of general mental health, distress, or depression. When distress is measured, but is not an outcome variable of the study (but a predictor or mediator, etc.) studies are excluded. Sequence generation: Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.
Appendix E. Variables included in data extraction form
Allocation concealment: Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.
Blinding of participants, personnel and outcome assessors: Assessments should be made for each main outcome (or class of outcomes). Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.
Incomplete outcome data: Assessments should be made for each main outcome (or class of outcomes). Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors.
Selective outcome reporting: State how the possibility of selective outcome reporting was examined by the review authors, and what was found.
Pharmaceutical industry funding: State the funding source(s) of the trial, or indicate if the trial funding source was not reported.
Author-industry financial ties and/or employment: State whether any trial authors disclosed financial ties and/or employment by the pharmaceutical industry, or if author-industry financial ties or affiliation were not reported.
Other sources of bias: State any important concerns about bias not addressed in the other domains in the tool. If particular questions/ entries were pre-specified in the review's protocol, responses should be provided for each question/entry.
